Median Technologies Raises €50M in Oversubscribed Capital Increase
Event summary
- Median Technologies raised €50M in an upsized capital increase, exceeding initial €40M target.
- The offering was multiple times oversubscribed, with strong demand from institutional and retail investors.
- Proceeds will fund commercialization of eyonis® LCS in the U.S. and Europe, and expansion into additional cancer indications.
- The capital increase extends the company's cash runway until the first half of 2028, potentially to mid-2029 with full exercise of warrants.
- New shares were issued at a discount of 2.85% to the 20-day VWAP and 11.3% to the closing price on May 26, 2026.
The big picture
Median Technologies' successful €50M capital raise underscores strong investor confidence in AI-powered early cancer diagnosis. The funding will accelerate the commercialization of its eyonis® platform, positioning the company to capitalize on the growing demand for advanced diagnostic tools in oncology. The oversubscription and participation from leading institutional investors highlight the strategic importance of AI in transforming cancer care and the biopharmaceutical industry's reliance on innovative imaging services for clinical trials.
What we're watching
- Commercial Execution
- Whether Median can successfully deploy eyonis® LCS in the U.S. and launch in Europe following CE marking.
- Platform Expansion
- The pace at which Median expands its eyonis® platform into additional cancer indications.
- Investor Confidence
- How the new institutional investors will influence the company's strategic direction and governance.
Related topics